Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector. - sprookjes - yvandenbroek - TriplyDB

Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector.

Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector.

http://www.wikidata.org/entity/Q37478331

about

Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination An immune competent mouse model for the characterization of recombinant measles vaccines.Applications and challenges of multivalent recombinant vaccines.RNA-based viral vectors.Vaccine platform recombinant measles virus.Measles virus.

P2860

Q26700080-E57A25CF-096F-4986-8277-084477146E84 Q35887095-D828449F-AB4A-4874-8A27-64897288A982 Q38068270-2FFC4C0B-8868-4195-BBB2-873ED2860F1A Q38266413-07E7266E-A1BF-40C2-94AB-9AA83801912B Q38657271-CCCBC9CC-5386-4E23-959B-95F417B8DAF8 Q41612319-F88616E7-556F-4273-9759-4D9DF4D59D46

P2860

Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector.

http://www.wikidata.org/entity/Q37478331

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 16 January 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector.

@en

Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector.

@nl

type

label

Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector.

@en

Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector.

@nl

prefLabel

Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector.

@en

Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector.

@nl

P1433

Q37478331-F0FBC88D-701A-4751-B130-FD62F00F50BD

P1476

Q37478331-A2B6DF0A-3315-4FB4-AD00-4DF1AE0BDB5F

P2093

Q37478331-15FB12AC-700D-470F-BBED-9556BAF93D1D

Q37478331-1925D983-5AB2-4E05-9612-A8467F1A2EB3

Q37478331-5563509E-ED46-4C87-B4AF-6D457FE92D20

Q37478331-5EEFB4B8-9377-4322-B7FD-09DD546EEB47

Q37478331-67BF95F6-218E-4F1B-BC1B-7475B48D9905

Q37478331-9122CB75-100D-4686-B822-2026BC74DDB1

Q37478331-C9B1061C-14C0-474E-BC76-926E1CA91AC5

Q37478331-CE937EAB-2031-4BF1-A078-7DB6B72DB05F

Q37478331-DA40B857-E3F4-4129-8248-8D94790130F3

Q37478331-EE5B2002-5AB4-4EC5-BDE8-34DF865E0858

P2860

Q37478331-0275B4F2-34E3-4190-862E-BC0FB16E9C63

Q37478331-0590289C-8900-4319-A26B-7CCF10B91C00

Q37478331-0DC1332F-36B1-43A5-95D2-A384616727AC

Q37478331-1317DBCE-B45D-44E1-94B6-89CAD607314E

Q37478331-152BB546-03F4-49CC-92AB-A1AEABCEFBBC

Q37478331-1AA93DEA-4F38-4323-9109-7FB7FCD29396

Q37478331-21CCF69A-5D7A-4088-BF53-75F485DD430D

Q37478331-22022679-D6B9-444D-A81B-CCFACF1996C6

Q37478331-2266DD33-9DE5-4C2A-862C-9AC766882577

Q37478331-29CD3B5A-AA26-42ED-9A02-A526B1A185C9

P304

Q37478331-69F15BEB-F5C0-4265-95DE-09854F09A7B9

P31

Q37478331-367D4BBD-F505-4E9D-95BD-2943AF717B35

P356

Q37478331-99657282-C803-48E0-88C7-645DD087291D

P433

Q37478331-DBA66868-97EE-4530-8342-653419AE0F0F

P478

Q37478331-7CB0515E-6079-4E11-8621-9501DD9E7C79

P577

Q37478331-01BA9EBF-51C2-4255-855E-A17BF99D6AF9

P5875

Q37478331-CC111654-4BBB-4AE3-BDE4-DDFAC5889A18

P698

Q37478331-AB4FDB46-EF75-48BA-ACBE-53101F79699E

P921

Q37478331-04AA534A-886C-41C1-80D3-7CEB4F8FB333

Q37478331-E6D44F05-3DEF-4EA7-8CDD-2CF5DB28C17F

P932

Q37478331-3C22E5F4-0E72-4E37-B662-874DA08A1373

P356

P1433

Human Vaccines & Immunotherapeutics

P1476

Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector.

@en

P2093

Amando Zuniga

http://www.w3.org/2001/XMLSchema#string

Hussein Y Naim

http://www.w3.org/2001/XMLSchema#string

Marian Wiegand

http://www.w3.org/2001/XMLSchema#string

Marlyse C Knuchel

http://www.w3.org/2001/XMLSchema#string

Martin A Billeter

http://www.w3.org/2001/XMLSchema#string

Mathias Liniger

http://www.w3.org/2001/XMLSchema#string

Orhan Ilter

http://www.w3.org/2001/XMLSchema#string

René R Marty

http://www.w3.org/2001/XMLSchema#string

Sara Weibel

http://www.w3.org/2001/XMLSchema#string

Teldja Neige Azzouz Morin

http://www.w3.org/2001/XMLSchema#string

P2860

The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?

Chimeric measles viruses with a foreign envelope

Measles virus spread and pathogenesis in genetically modified mice.

Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles.

Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans.

An HIV vaccine--challenges and prospects.

Viral vectors as potential HIV-1 vaccines.

A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV.

Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women.

A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge.

P304

607-613

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/HV.23242

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234157233

http://www.w3.org/2001/XMLSchema#string

P698

23324616

http://www.w3.org/2001/XMLSchema#string

P921

vector-borne disease

P932

3891718

http://www.w3.org/2001/XMLSchema#string